Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Medtronic

Medtronic and Merck are innovative healthcare leaders. Both are developing new products to keep sales growing.

Bull Market and Beyond: 2 Stocks to Buy and Hold Forever

Merck said on Thursday a combination of its cancer drugs Keytruda and Lynparza failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.

Merck combination treatment for lung cancer fails late-stage study

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). In the KEYLYNK-006 tri.

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.

Merck (MRK) Laps the Stock Market: Here's Why

NEW YORK--(BUSINESS WIRE)-- #biotech--Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson's Digital Biomarkers Observational Study.

Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson's Digital Biomarkers Observational Study

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Data on V116, an Investigational, 21-Valent PCV Specifically Designed for Adults, Demonstrated Immune Responses in Adults.

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel , March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

Merck said on Friday its drug Keytruda, in combination with chemoradiotherapy, met the main goal in a late-stage study in newly diagnosed patients with high-risk locally advanced cervical cancer.

Merck's cervical cancer therapy met main goal in late-stage study

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus CRT Significantly Improved OS Vs. CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer.

Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck (MRK) concluded the recent trading session at $120.51, signifying a -1.35% move from its prior day's close.

Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know

Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.

Here's Why Merck (MRK) Fell More Than Broader Market

Amazon

Salesforce

McDonald's

Microsoft

NIKE

The month of March has a reputation for being among the more volatile ones for the stock market. The NCAA basketball tournament known as March Madness also occurs during the month.

7 Dow Darlings for Investors to Buy for March Market Madness

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Merck & Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a single-dose regimen compared to the approved three-dose regimen.

Merck to test single-dose regimen of HPV vaccine Gardasil 9

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent HPV Vaccine and Single-Dose Regimen for GARDASIL®9.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biomedicalengineering--Pearl Bio inks $1B biobucks deal with Merck, paving the road for evolution of next-generation programmable biologics.

Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics

Merck & Co., Inc. (NYSE:MRK ) Leerink Partners 2024 Global Biopharma Conference Call March 11, 2024 12:40 PM ET Company Participants Marjorie Green - SVP and Head of Oncology Peter Dannenbaum - VP, IR Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Hi, everyone. Thank you for coming to the session.

Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript)

Block

Dow Jones leader Merck, Square stock and Fifth Third Bancorp are in or near buy zones in Monday's stock market action.

Dow Jones Leader Merck, Square Stock Are In Or Near Buy Zones In Today's Stock Market

Harpoon Therapeutics Inc

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, pr.

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

AbbVie

Both of these healthcare giants are leaders in their industries and faithful dividend payers. AbbVie is dealing with short-term challenges, but the strength of its underlying business remains intact.

Have $2,500? 2 Superior Growth Stocks to Buy in 2024

Gilead Sciences

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor. These late-breaking data were presented during an oral session at the 31st Conference on.

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck & Co., Inc. (NYSE:MRK ) TD Cowen 44th Annual Healthcare Conference March 5, 2024 1:30 PM ET Company Participants Joe Romanelli - President of Human Health International Peter Dannenbaum - Head of Investor Relations Conference Call Participants Steve Scala - Cowen Steve Scala We are delighted to have Merck here at Cowen's 44th Annual Healthcare Conference. Representing the Company, Joe Romanelli, who is President of Human Health International.

Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Barclays 26th Annual Global Healthcare Conference.

Merck to Participate in the Barclays 26th Annual Global Healthcare Conference

American Express

The Dow Jones Industrial Average is the oldest U.S. market index, created on May 26, 1896. Throughout history, its components have been large, established American businesses with competitive advantages.

News for Merck Stock (MRK)